Chrousos Phaedra 4

What Happened

• Phaedra Chrousos, a director of Vanda Pharmaceuticals (VNDA), received a grant of 41,600 restricted stock units (RSUs) on June 4, 2026. The reported acquisition price is $0.00, so no cash was exchanged for the award.
• The award represents the right to 41,600 shares of Vanda common stock that will convert to actual shares if and when the RSUs vest.

Key Details

• Transaction date: June 4, 2026. Filing date: June 8, 2026 (see note on timeliness below).
• Transaction type/code: Award/Grant (A).
• Shares granted: 41,600 RSUs. Reported acquisition price: $0.00 (award, not a purchase).
• Vesting: 100% of the RSUs vest on June 4, 2027, provided Chrousos remains in continuous service through that date (footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: The Form 4 was filed four days after the transaction; Form 4s are generally required within two business days, so this filing appears to be late.

Context

• RSUs are a time-based equity award — they do not represent immediate tradable shares until they vest. This is a standard form of executive/director compensation and does not by itself indicate buying or selling sentiment.
• Because this was an award (not a purchase or sale), there was no cash exchanged and no immediate change in market exposure until the RSUs vest and convert to shares (assuming continued service).